BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14748202)

  • 1. [Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease].
    Scheen AJ; Legrand V
    Rev Med Liege; 2003 Nov; 58(11):713-6. PubMed ID: 14748202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
    Fox KM;
    Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.
    Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML;
    Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.
    Bertrand ME; Fox KM; Remme WJ; Ferrari R; Simoons ML
    Arch Cardiovasc Dis; 2009 Feb; 102(2):89-96. PubMed ID: 19303575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
    Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
    Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
    Fox KM; Bertrand ME; Remme WJ; Ferrari R; Simoons ML; Deckers JW;
    Am Heart J; 2007 Apr; 153(4):629-35. PubMed ID: 17383303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model.
    Oemrawsingh RM; Akkerhuis KM; Van Vark LC; Redekop WK; Rudez G; Remme WJ; Bertrand ME; Fox KM; Ferrari R; Danser AH; de Maat M; Simoons ML; Brugts JJ; Boersma E;
    J Am Heart Assoc; 2016 Mar; 5(3):e002688. PubMed ID: 27021566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
    Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
    Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
    Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
    Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
    Boos CJ
    Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
    Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
    Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ACE-inhibitor effects on the stabilization of coronary heart disease. EUROPA study].
    Böhm M
    Internist (Berl); 2004 Oct; 45(10):1196-8. PubMed ID: 15372169
    [No Abstract]   [Full Text] [Related]  

  • 17. Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?
    Remme WJ; Deckers JW; Fox KM; Ferrari R; Bertrand M; Simoons ML;
    Cardiovasc Drugs Ther; 2009 Apr; 23(2):161-70. PubMed ID: 18931896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
    Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.
    Bots ML; Remme WJ; Lüscher TF; Fox KM; Bertrand M; Ferrari R; Simoons ML; Grobbee DE;
    Cardiovasc Drugs Ther; 2007 Aug; 21(4):269-79. PubMed ID: 17657599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.